{"id":"https://genegraph.clinicalgenome.org/r/4469ccec-b8ae-4e2d-84dc-d468775361cdv1.0","type":"EvidenceStrengthAssertion","dc:description":"FANCE is one of the 23 FA or FA-like genes known to cause autosomal recessive Fanconi anemia (FA) characterized by bone marrow failure, developmental abnormalities, cancer predisposition, and cellular hypersensitivity to DNA cross-linking agents such as mitomycin C. The first patients with FA complementation group E were reported in 1996 (PMID: 9147877, 7662964). Five homozygous variants in the FANCE gene were observed in individuals with FA complementation group E, and three of these variants were reported to segregate with disease in three small families, suggesting homozygous loss of function is the mechanism of tumorigenesis for this disorder (PMID: 11001585, 17924555). This gene-disease relationship is further supported by rescue cell culture model, protein interaction and functional alteration studies. In summary, FANCE is definitively associated with FA complementation group E. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/4469ccec-b8ae-4e2d-84dc-d468775361cd","GCISnapshot":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2020-09-16T19:22:58.222Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2020-05-14T00:17:45.604Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a40c9230-ff88-421a-9e3e-77363847dd9e","type":"EvidenceLine","dc:description":"The rescue experiments indicate that FANCE is required for the monoubiquitination of FANCD2 and downstream events in the FA pathway, providing compelling evidence for FANCE as a causative gene in FA patients.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/66ddd18d-c790-43b7-a7ec-42e16158e232","type":"Finding","dc:description":"Transfection with FANCE in EUFA130 (the FANCE null cell line) corrected the MMC sensitivity of 3 independent FA-E lymphoblast cell linesâ€”EUFA130, EUFA410, and EUFA622 (Fig. 1A). In EUFA130, FANCA/FANCC binding was not observed, but when transfected with FANCE, FANCA/FANCC binding was restored (Fig. 1B), as was monoubiquitination of FANCD2 (Fig. 1C). In EUFA130, FANCD2 is expressed in a diffuse nuclear pattern, transfection with FANCE restores FANCD2 nuclear foci (Fig. 1D).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12239156","rdfs:label":"MMC sensitivity, Immunoprecipitation and Immunoblotting","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8789149d-7f4d-4779-9170-84577e828261","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e5d6a27a-ea5d-4fd9-b36f-71f34fc35f39","type":"FunctionalAlteration","dc:description":"In Yeast two-hybrid analysis, FANCE F522D with C-terminal 25 amino acids deletion is expressed at a similar level to that of wild type FANCE, but failed to interact with FANCD2. In co-immunoprecipitation assay,  a small fraction of FANCD2 was present only in the wild type FANCE IP, and not in the FANCE F522D mutant IP, confirming that the mutant was unable to interact with FANCD2.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24451376","rdfs:label":"Yeast two-hybrid analysis, co-immunoprecipitation assay"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ccc261a3-3795-4b28-9dd2-391145f9e58a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5b5c8797-bcca-43f2-bd95-a819dc82b05f","type":"FunctionalAlteration","dc:description":"To identify a critical region of FANCE required for promoting the FANCD2 monoubiquitination and the FA pathway, serial truncations of FANCE were made and expressed in a patient-derived FANCE null lymphoblast cell line (EUFA130). All of the mutants that lacked the extreme C terminus of FANCE failed to restore monoubiquitination of FANCD2 and resistance to MMC.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24451376","rdfs:label":"MMC survival assays and the FANCD2 monoubiquitination"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a214390b-6944-43ad-a1bf-1a2b6fd08090","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34219ec7-ce19-4413-99cc-3ae08537a52f","type":"FunctionalAlteration","dc:description":"When tested in the yeast two-hybrid assay, no interaction was observed between the R371W FANCE protein and FANCD2 (Figure 5). This data provides a structural rationale for the pathological effect of the R371 mutation in FANCE.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17308347","rdfs:label":"Structure-based yeast two-hybrid analysis"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc8a9de9-095e-44cd-83ea-fbb8b75b9de0","type":"EvidenceLine","dc:description":"The protein interaction is confirmed by another co-immunoprecipitation assay independently, further suggesting the association of FANCE and other FA core members (FANCA, FANCC, FANCG) PMID: 24451376","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16d1ac50-932e-45c8-b2af-64e3e85651b2","type":"Finding","dc:description":"Co-immunoprecipitation experiments were performed using HeLa cells stably transfected with HA-FANCE. HA-FANCE was co-immunoprecipitated by anti-FANCA, anti-FANCC, or anti-FANCG antibodies. These results indicate that FANCE interacts with other components of the FA complex in vivo.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12239156","rdfs:label":"Immunoprecipitation","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05769788-34d7-49e5-b51a-151859f3a635_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This sequence change creates a premature translational stop signal (p.Gln119*) in the FANCE gene. It is expected to result in an absent or disrupted protein product. This variant has been classified as Pathogenic in ClinVar. Lymphoblasts derived from EUFA130 has been used as a patient-derived FANCE null reference cell line. The parents and unaffected brother were heterozygous for this mutation.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4023aef4-74b4-4dfb-b4af-d90948b2a60f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","rdfs:label":"EUFA130","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"phenotypes from PMID: 9147877","phenotypes":["obo:HP_0002750","obo:HP_0001510","obo:HP_0001156","obo:HP_0001159","obo:HP_0000286","obo:HP_0000601","obo:HP_0000086","obo:HP_0000248","obo:HP_0025356","obo:HP_0000028","obo:HP_0032188"],"previousTesting":true,"previousTestingDescription":"By use of homozygosity mapping and standard linkage analysis, the location of the FANCE gene was identified on chromosome 6p.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/05769788-34d7-49e5-b51a-151859f3a635_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","allele":{"id":"https://genegraph.clinicalgenome.org/r/6ac8d001-cc1d-4074-a282-f802d15c4fb3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021922.2(FANCE):c.355C>T (p.Gln119Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254528"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/31e23354-be99-4417-bdd0-433479c30726_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Sequence analysis of cDNA derived from EUFA622 indicated that this mutation results in false splicing and incorporation of six nucleotides from intron 5, including an in-frame stop codon.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8119e899-b404-4960-9f2a-46d15a473a45","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","rdfs:label":"EUFA622","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Clinical features of the patient EUFA622 was documented by A. Koc, M. Alikasifoglu, H. Joenje, and C. Altay, unpublished data.","phenotypes":"obo:HP_0032188","previousTesting":true,"previousTestingDescription":"By use of homozygosity mapping and standard linkage analysis, the location of the FANCE gene was identified on chromosome 6p.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/31e23354-be99-4417-bdd0-433479c30726_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","allele":{"id":"https://genegraph.clinicalgenome.org/r/c3b6d7e8-cf4f-4738-b663-870bd5b1d2e1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021922.2(FANCE):c.1114-8G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575503"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/758d450a-c84d-4d0d-ab2a-00aaebf59c98_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant is one of the transcript alleles under CA363770085.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78891a98-d0d7-4cfd-ad33-bad0e9f2903e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17924555","rdfs:label":"FANCE patient with variant p.Q31X","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0032188","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/758d450a-c84d-4d0d-ab2a-00aaebf59c98_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17924555","allele":{"id":"https://genegraph.clinicalgenome.org/r/aceda6fe-937b-4cce-8500-c4cb58e9cb60","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"XR_002956267.1(FANCE):n.298C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA363770085"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6da55a6e-2cf8-499c-b842-b5a435dbff3f_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2ccbb2a-18b3-43e9-af1e-ba71f0c15c15_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","rdfs:label":"Family 3 (patient EUFA622) of Turkish origin","estimatedLodScore":0.12,"family":{"id":"https://genegraph.clinicalgenome.org/r/b2ccbb2a-18b3-43e9-af1e-ba71f0c15c15","type":"Family","rdfs:label":"Family 3 (patient EUFA622) of Turkish origin","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/8119e899-b404-4960-9f2a-46d15a473a45"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/8119e899-b404-4960-9f2a-46d15a473a45"}},{"id":"https://genegraph.clinicalgenome.org/r/65c79f56-6cdd-466c-9bb9-5711ac696864_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","rdfs:label":"Family 1 of Turkish origin","estimatedLodScore":0.12,"family":{"id":"https://genegraph.clinicalgenome.org/r/65c79f56-6cdd-466c-9bb9-5711ac696864","type":"Family","rdfs:label":"Family 1 of Turkish origin","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/4023aef4-74b4-4dfb-b4af-d90948b2a60f"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/4023aef4-74b4-4dfb-b4af-d90948b2a60f"}},{"id":"https://genegraph.clinicalgenome.org/r/b4afb582-1934-4c11-8f6c-bcabcc5ddc53_proband_segregation","type":"FamilyCosegregation","dc:description":"A homozygous C to T transition in exon 2 of EUFA410, which changes codon 141 into a stop codon (R141X; table 1). The parents were heterozygous for this mutation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","rdfs:label":"Family 2 from Banglades(PMID: 10205272)","estimatedLodScore":1.33,"family":{"id":"https://genegraph.clinicalgenome.org/r/b4afb582-1934-4c11-8f6c-bcabcc5ddc53","type":"Family","rdfs:label":"Family 2 from Banglades(PMID: 10205272)","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/2a835da8-2888-484c-9b4b-3427103789ce","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","rdfs:label":"EUFA410","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0032188","obo:HP_0002247","obo:HP_0000238","obo:HP_0000086","obo:HP_0002984"],"previousTesting":true,"previousTestingDescription":"By use of homozygosity mapping and standard linkage analysis, the location of the FANCE gene was identified on chromosome 6p.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/08cf0ae7-cae4-4628-8b1c-4c53f2967af3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001585","allele":{"id":"https://genegraph.clinicalgenome.org/r/9d254480-ba8e-4052-86da-c2f8e183295f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021922.2(FANCE):c.421C>T (p.Arg141Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254531"}}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Radial ray defects, renal ectopia, duodenal atresia and hydrocephalus","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":3,"proband":{"id":"https://genegraph.clinicalgenome.org/r/2a835da8-2888-484c-9b4b-3427103789ce"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/76a7ce6e-06e8-41a7-9d5e-54c2e35c79cd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"It was reported that FANCE protein was not expressed in patient with this variant. This homozygous variant was detected in another cohort of 54 patients. (PMID: 22778927); Function alteration study showed that this variant interrupts the interaction between FANCE protein and FANCD2.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ea866f2-71e8-4b01-b22d-b993703e7ff0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17924555","rdfs:label":"FANCE patient with variant p.R371W","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"DHPLC and sequencing of aberrant fragments","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0032188","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/76a7ce6e-06e8-41a7-9d5e-54c2e35c79cd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17924555","allele":{"id":"https://genegraph.clinicalgenome.org/r/9285f539-daf7-42ee-8a0e-f654f3501db6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_021922.2(FANCE):c.1111C>T (p.Arg371Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/566449"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/08cf0ae7-cae4-4628-8b1c-4c53f2967af3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The parents were heterozygous for this mutation.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a835da8-2888-484c-9b4b-3427103789ce"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":10}],"evidenceStrength":"Definitive","sequence":743,"specifiedBy":"GeneValidityCriteria7","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/ddyxkZ0rC4E","type":"GeneValidityProposition","disease":"obo:MONDO_0010953","gene":"hgnc:3586","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_6da55a6e-2cf8-499c-b842-b5a435dbff3f-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}